FOLD – Amicus Therapeutics, Inc.
Float Short %
6.46
Margin Of Safety %
-33
Put/Call OI Ratio
1.04
EPS Next Q Diff
-0.08
EPS Last/This Y
0.56
EPS This/Next Y
0.27
Price
14.29
Target Price
14.8
Analyst Recom
2.71
Performance Q
75.25
Relative Volume
0.98
Beta
0.38
Ticker: FOLD
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-09 | FOLD | 9.8 | 0.71 | 0.13 | 26231 |
| 2025-12-10 | FOLD | 9.85 | 0.71 | 0.28 | 26221 |
| 2025-12-11 | FOLD | 9.9 | 0.71 | 0.07 | 26239 |
| 2025-12-12 | FOLD | 10.55 | 0.71 | 0.01 | 26356 |
| 2025-12-15 | FOLD | 10.89 | 0.69 | 0.42 | 26819 |
| 2025-12-16 | FOLD | 10.9 | 0.72 | 0.57 | 30925 |
| 2025-12-17 | FOLD | 10.99 | 0.72 | 0.03 | 31335 |
| 2025-12-18 | FOLD | 10.9 | 0.71 | 0.56 | 31688 |
| 2025-12-19 | FOLD | 14.2 | 0.71 | 1.35 | 31577 |
| 2025-12-22 | FOLD | 14.2 | 1.02 | 0.83 | 32121 |
| 2025-12-23 | FOLD | 14.22 | 1.03 | 0.80 | 33251 |
| 2025-12-26 | FOLD | 14.25 | 1.02 | 2.16 | 33805 |
| 2025-12-29 | FOLD | 14.25 | 1.03 | 1.42 | 33877 |
| 2025-12-30 | FOLD | 14.24 | 1.04 | 2.76 | 34130 |
| 2025-12-31 | FOLD | 14.24 | 1.06 | 0.03 | 34781 |
| 2026-01-02 | FOLD | 14.25 | 1.07 | 2.57 | 34896 |
| 2026-01-05 | FOLD | 14.24 | 1.06 | 0.21 | 34772 |
| 2026-01-06 | FOLD | 14.28 | 1.03 | 2.28 | 35377 |
| 2026-01-07 | FOLD | 14.29 | 1.04 | 1.30 | 35498 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-09 | FOLD | 9.81 | 77.8 | 155.6 | 0.37 |
| 2025-12-10 | FOLD | 9.81 | 77.8 | 157.5 | 0.37 |
| 2025-12-11 | FOLD | 9.90 | 77.8 | 157.3 | 0.37 |
| 2025-12-12 | FOLD | 10.55 | 77.8 | 169.5 | 0.37 |
| 2025-12-15 | FOLD | 10.88 | 77.8 | 162.7 | 0.37 |
| 2025-12-16 | FOLD | 10.88 | 77.8 | 156.8 | 0.37 |
| 2025-12-17 | FOLD | 10.98 | 77.8 | 158.1 | 0.37 |
| 2025-12-18 | FOLD | 10.90 | 77.8 | 154.7 | 0.37 |
| 2025-12-19 | FOLD | 14.20 | 77.8 | 216.3 | 0.37 |
| 2025-12-22 | FOLD | 14.23 | 84.1 | 156.8 | 0.38 |
| 2025-12-23 | FOLD | 14.22 | 83.2 | 156.6 | 0.38 |
| 2025-12-26 | FOLD | 14.26 | 83.2 | 156.7 | 0.38 |
| 2025-12-29 | FOLD | 14.25 | 83.2 | 156.5 | 0.38 |
| 2025-12-30 | FOLD | 14.24 | 83.2 | 156.4 | 0.38 |
| 2025-12-31 | FOLD | 14.24 | 83.2 | 156.4 | 0.38 |
| 2026-01-02 | FOLD | 14.26 | 83.2 | 156.8 | 0.38 |
| 2026-01-05 | FOLD | 14.24 | 83.2 | 156.1 | 0.38 |
| 2026-01-06 | FOLD | 14.27 | 83.2 | 157.1 | 0.38 |
| 2026-01-07 | FOLD | 14.29 | 83.2 | 156.7 | 0.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-09 | FOLD | -3.78 | -0.84 | 5.97 |
| 2025-12-10 | FOLD | -3.78 | -0.84 | 6.39 |
| 2025-12-11 | FOLD | -3.78 | -0.84 | 6.39 |
| 2025-12-12 | FOLD | -3.78 | -0.84 | 6.39 |
| 2025-12-15 | FOLD | -3.78 | -0.84 | 6.39 |
| 2025-12-16 | FOLD | -3.78 | -0.84 | 6.39 |
| 2025-12-17 | FOLD | -3.78 | -0.84 | 6.39 |
| 2025-12-18 | FOLD | -5.25 | -0.84 | 6.39 |
| 2025-12-19 | FOLD | -5.25 | -0.84 | 6.39 |
| 2025-12-22 | FOLD | -5.25 | -0.84 | 6.39 |
| 2025-12-23 | FOLD | -5.28 | -0.84 | 6.39 |
| 2025-12-26 | FOLD | -5.62 | -0.84 | 6.47 |
| 2025-12-29 | FOLD | -5.62 | -0.83 | 6.47 |
| 2025-12-30 | FOLD | -5.65 | -0.83 | 6.47 |
| 2025-12-31 | FOLD | -5.65 | -0.83 | 6.47 |
| 2026-01-02 | FOLD | -5.65 | -0.83 | 6.47 |
| 2026-01-05 | FOLD | -5.65 | -0.85 | 6.46 |
| 2026-01-06 | FOLD | -5.81 | -0.85 | 6.46 |
| 2026-01-07 | FOLD | -5.81 | -0.85 | 6.46 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.17
Avg. EPS Est. Current Quarter
0.16
Avg. EPS Est. Next Quarter
0.09
Insider Transactions
-5.81
Institutional Transactions
-0.85
Beta
0.38
Average Sales Estimate Current Quarter
179
Average Sales Estimate Next Quarter
162
Fair Value
9.61
Quality Score
59
Growth Score
72
Sentiment Score
44
Actual DrawDown %
40.9
Max Drawdown 5-Year %
-76.4
Target Price
14.8
P/E
Forward P/E
53.24
PEG
P/S
7.39
P/B
19.15
P/Free Cash Flow
456.46
EPS
-0.04
Average EPS Est. Cur. Y
0.38
EPS Next Y. (Est.)
0.65
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2.35
Relative Volume
0.98
Return on Equity vs Sector %
-33.2
Return on Equity vs Industry %
-18
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
156.7
Amicus Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 499
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
stock quote shares FOLD – Amicus Therapeutics, Inc. Stock Price stock today
news today FOLD – Amicus Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FOLD – Amicus Therapeutics, Inc. yahoo finance google finance
stock history FOLD – Amicus Therapeutics, Inc. invest stock market
stock prices FOLD premarket after hours
ticker FOLD fair value insiders trading